ArticleJournal of virology2013
A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.
Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 73 citations in OpenAlex.
- Trial
- Review
- Comparison of the induction of neutralizing antibodies against Bas congo virus using several vaccine modalities.Scientific reports · 2025Article
- West Nile virus - a re-emerging global threat: recent advances in vaccines and drug discovery.Frontiers in cellular and infection microbiology · 2025Review
- Article
- Protein characterization of an Indonesian isolate of foot and mouth disease virus inactivated with formaldehyde and binary ethylenimine.Veterinary world · 2024Article
- Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.Cell reports. Medicine · 2024Article
- Precise modulation and use of reactive oxygen species for immunotherapy.Science advances · 2024Review
- Efficacy of HBMC veterinary research · 2024Article
- Manipulation of Oxidative Stress Responses by Non-Thermal Plasma to Treat Herpes Simplex Virus Type 1 Infection and Disease.International journal of molecular sciences · 2023Review
- Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus.Vaccines · 2023Article
- Immunization with different recombinant West Nile virus envelope proteins induces varying levels of serological cross-reactivity and protection from infection.Frontiers in cellular and infection microbiology · 2023Article
- Comparing the Immunogenicity and Protective Effects of Three MERS-CoV Inactivation Methods in Mice.Vaccines · 2022Article
- Development of a next-generation chikungunya virus vaccine based on the HydroVax platform.PLoS pathogens · 2022Article
- Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes.Pathogens (Basel, Switzerland) · 2022Review
- Testing Novel Inactivation Methods and Adjuvants for Vaccines Against Streptococcus agalactiae in Nile Tilapia Oreochromis niloticus.Methods in molecular biology (Clifton, N.J.) · 2022Article
- An Overview of Veterinary Viral Diseases and Vaccine Technologies.Methods in molecular biology (Clifton, N.J.) · 2022Review
- Immunity to acute virus infections with advanced age.Current opinion in virology · 2021Review
- Obesity Enhances Disease Severity in Female Mice Following West Nile Virus Infection.Frontiers in immunology · 2021Article
- In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine.Vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
West Nile virus (WNV) is an emerging pathogen that is now the leading cause of mosquito-borne and epidemic encephalitis in the United States. In humans, a small percentage of infected individuals develop severe neuroinvasive disease, with the greatest relative risk being in the elderly and immunocompromised, two populations that are difficult to immunize effectively with vaccines. While inactivated and subunit-based veterinary vaccines against WNV exist, currently there is no vaccine or therapy available to prevent or treat human disease. Here, we describe the generation and preclinical efficacy of a hydrogen peroxide (H(2)O(2))-inactivated WNV Kunjin strain (WNV-KUNV) vaccine as a candidate for further development. Both young and aged mice vaccinated with H(2)O(2)-inactivated WNV-KUNV produced robust adaptive B and T cell immune responses and were protected against stringent and lethal intracranial challenge with a heterologous virulent North American WNV strain. Our studies suggest that the H(2)O(2)-inactivated WNV-KUNV vaccine is safe and immunogenic and may be suitable for protection against WNV infection in vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.